Abstract |
The management of diabetic macular edema (DME) has been revolutionized in recent years. Focal and focal/ grid laser photocoagulation have been the mainstay of treatment for DME for much time. However, nowadays, there is growing evidence that intravitreal VEGF-inhibitors (combined or not with laser photocoagulation) provide better visual outcome in patients with diabetic retinopathy. Hence, anti- VEGF injections are considered the new gold standard to treat diabetic macular edema and eyes with a reduced visual function. Further studies assessing different treatment regimens are underway to define better clinical care pathways.
|
Authors | Nicola Pescosolido, Federica Pranno, Giuseppe Buomprisco |
Journal | Current diabetes reviews
(Curr Diabetes Rev)
Vol. 9
Issue 6
Pg. 491-8
(Nov 2013)
ISSN: 1875-6417 [Electronic] United Arab Emirates |
PMID | 24160355
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Combined Modality Therapy
- Diabetic Retinopathy
(pathology, therapy)
- Female
- Humans
- Intravitreal Injections
- Laser Coagulation
(methods)
- Macular Edema
(pathology, therapy)
- Male
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
|